A laboratory approach for characterizing chronic fatigue: what does metabolomics tell us?
Elardus ErasmusShayne MasonMari van ReenenFrancois E SteffensB Chris VorsterCarolus J ReineckePublished in: Metabolomics : Official journal of the Metabolomic Society (2019)
Untargeted 1H-NMR metabolomics proved its applicability as a global profiling tool to reveal the impact of toxicological interventions in chronic fatigue patients. No clear potential biomarker emerged from this study, but the quantitative profile of the phase II biotransformation products provide a practical visible effect directing to up-regulation of crucial phase II enzyme systems in the high fatigue group in response to a high xenobiotic-load.
Keyphrases
- phase ii
- clinical trial
- open label
- mass spectrometry
- end stage renal disease
- sleep quality
- phase iii
- newly diagnosed
- ejection fraction
- chronic kidney disease
- magnetic resonance
- placebo controlled
- double blind
- single cell
- physical activity
- depressive symptoms
- patient reported outcomes
- peritoneal dialysis
- dna methylation
- solid state
- high resolution mass spectrometry